Our flagship webinar series is integral to the technical assistance provided by SCLC, reaching providers, advocates, public health practitioners, and community members nationwide. Nationally recognized researchers, public health leaders, and community-based organizations share the latest information and strategies related to tobacco cessation.
65,000+ community members reached
150+ webinars on tobacco addiction, cessation, and recovery
The SCLC Webinar Series Will...
Provide Training & Technical Assistance
Raise awareness of the benefits of tobacco cessation, increase understanding of effective cessation strategies, and support the implementation or enhancement of evidence-based tobacco cessation services.
Educate
Educate people who use tobacco and staff in healthcare and behavioral health facilities about tobacco treatment to promote health and wellness.
Strengthen Community Partnerships
Build community capacity for tobacco cessation and better serve populations disproportionately impacted by tobacco use.
Upcoming Webinars
Can GLP-1 Receptor Agonists Help People Quit Smoking — and Who Might Benefit Most?
Associate Professor, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, John P. and Kathrine G. McGovern Medical School, University of Texas Health Science Center at Houston
Luba Yammine, PhD is an Associate Professor in the Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences at McGovern Medical School at UTHealth Houston. Her research program focuses on developing and testing novel pharmacologic approaches for addiction treatment, with a particular emphasis on repurposing GLP-1-based therapies for tobacco use disorder and post-smoking-cessation weight management, and other substance use disorders.
Dr. Yammine led the first human trial of extended-release exenatide for smoking cessation and continues to investigate GLP-1–based approaches to addiction treatment. She currently serves as Principal Investigator or multiple Principal Investigator on several NIH-funded clinical trials, including two NIDA R01 studies investigating exenatide and semaglutide for tobacco and cocaine use disorders, as well as an investigator-sponsored clinical trial of semaglutide focused on weight management following smoking cessation, funded by Novo Nordisk. Her research has been published in peer-reviewed scientific journals and covered in national media, and she has presented her work at meetings and events organized by the National Institutes of Health and professional societies.
Webinar Objectives:
Upon completion of this webinar, participants will be able to:
Describe how GLP-1 receptor agonists may affect the brain's reward and craving pathways, and why researchers began studying them for smoking cessation.
Summarize the evidence linking GLP-1 receptor agonists to reduced tobacco use.
Explain why results have been mixed across studies and what factors may influence cessation outcomes.
Identify the key questions, limitations, and next steps that need to be addressed before GLP-1-based therapies can be considered a tool for treating tobacco addiction.
